Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors

被引：0
作者：
A. E. Gareeva [1 ]
L. S. Borodina [2 ]
S. A. Pozdnyakov [3 ]
I. F. Timerbulatov [4 ]
机构：
[1] Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa
[2] Kemerovo State University, Kemerovo
[3] Russian Medical Academy of Continuous Professional Education, Russian Ministry of Health, Moscow
[4] Republican Narcology Dispenser No. 1, Ministry of Health of the Republic of Bashkortostan, Ufa
[5] Moscow Scientific and Applied Narcology Center, Moscow City Health Department, Moscow
[6] Usoltsev Central Clinical Psychiatric Hospital, Moscow
[7] Russian Medical University, Russian Ministry of Health, Moscow
来源：
Neuroscience and Behavioral Physiology | 2024年 / 54卷 / 8期
关键词：
antidepressants; pharmacogenomics; pharmacometabolomics; selective serotonin reuptake inhibitors;
D O I：
10.1007/s11055-024-01716-5
中图分类号：
学科分类号：
摘要：
The efficacy and safety of psychopharmacotherapy with antidepressants is of great medical importance. The search for clinical and biological predictors for the selection of optimal psychopharmacotherapy with antidepressants is under active investigation throughout the world. Most studies address the search for associations between polymorphic variants of genes and the efficacy and safety of therapy. However, data on patients’ genetic polymorphisms are often insufficient for predicting the efficacy and safety of a drug. Contemporary research on the personalization of pharmacotherapy should include not only genetic, but also phenotypic biomarkers. This is important because genotyping, for example, cannot accurately predict the real metabolic activity of an isoenzyme. Successful treatment of depression remains a complex task; between-individual differences in responses to antidepressants are common. About half of patients with depressive disorders do not respond to the first attempt at antidepressant therapy. Serious side effects in pharmacotherapy with antidepressants and discontinuation of treatment due to intolerance are associated with lack of therapeutic efficacy. This review presents results from the latest studies of “omics” biomarkers of the efficacy and safety of antidepressants. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
引用
收藏
页码：1205 / 1214
页数：9
相关论文
共 86 条
  • [31] Cipriani A., Furukawa T.A., Salanti G., Et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, 391, pp. 1357-1366, (2018)
  • [32] Lundmark J., Reis M., Bengtsson F., Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting, Ther. Drug Monit, 22, 4, pp. 446-454, (2000)
  • [33] Hedayati S.S., Gregg L.P., Carmody T., Et al., Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: The CAST randomized clinical trial, JAMA, 318, 19, pp. 1876-1890, (2017)
  • [34] Reis M., Aberg-Wistedt A., Agren H., Et al., Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression, Hum. Psychopharmacol, 19, 5, pp. 283-291, (2004)
  • [35] Eap C.B., Grunder G., Baumann P., Et al., Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants, World J. Biol. Psychiatry, 22, 8, pp. 561-628, (2021)
  • [36] Kirchheiner J., Brosen K., Dahl M.L., Et al., CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages, Acta Psychiatr. Scand, 104, 3, pp. 173-192, (2001)
  • [37] Jukic M.M., Opel N., Strom J., Et al., Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment, Mol. Psychiatry, 22, No. 8, (2017)
  • [38] Nassan M., Nicholson W.T., Elliott M.A., Et al., Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: A template for psychiatric precision medicine, Mayo Clin. Proc, 91, 7, pp. 897-907, (2016)
  • [39] Suwala J., Machowska M., Wiela-Hojenska A., Venlafaxine pharmacogenetics: a comprehensive review, Pharmacogenomics, 20, 11, pp. 829-845, (2019)
  • [40] Ahmed A.T., Biernacka J.M., Jenkins G., Et al., Pharmacokinetic-pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram/escitalopram treatment failure, J. Affect. Disord, 246, pp. 62-68, (2019)
123456789